FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.
The upcoming two-day event delves into the clinical trial landscape and the strategies employed to increase the region’s attractiveness.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
J&J makes surgical robotic moves with Ottava FDA IDE application
Microbot eyes FDA application for surgical robot after completing pivotal trial
Rivanna starts trial for AI-enabled Accuro XV imaging system
NIH selects Emergex’s T cell vaccine for trials under Project NextGen